Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
ANN ARBOR, Mich., March 08, 2016 -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C, today announced Tim M. Mayleben, president and chief executive officer, will present at the Barclays Global Healthcare Conference in Miami, FL on Tuesday, March 15, 2016 at 8:30 A.M. Eastern Time.
Esperion's Commitment to Cardiometabolic Disease
Esperion is committed to improving the lives of patients by developing therapies to lower elevated LDL-C. Esperion scientists discovered bempedoic acid and the LDL-C lowering therapy is in late stage development. Esperion plans to develop both bempedoic acid and a fixed-dose combination of bempedoic acid and ezetimibe with a particular focus on patients with elevated LDL-C who are considered intolerant of statin therapy. It is estimated that approximately 10% of patients who are prescribed statins, 3.5 million patients in the U.S., are considered statin intolerant.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-C lowering therapies for the treatment of patients with elevated LDL-C. Bempedoic acid, the Company’s lead product candidate, is an inhibitor of ATP Citrate Lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol and up-regulates LDL-receptors, resulting in increased LDL-C clearance and reduced plasma levels of LDL-C. For more information, please visit www.esperion.com and follow us on Twitter at https://twitter.com/EsperionInc.
Media Contact: Elliot Fox W2O Group 212.257.6724 [email protected] Investor Contact: Mindy Lowe Esperion Therapeutics 734.887.3903 [email protected]
